- Home
- GUTS vs FBIO Comparison
GUTS vs FBIO Comparison
Compare GUTS & FBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GUTS
- FBIO
- Stock Information
- Founded
- GUTS 2010
- FBIO 2006
- Country
- GUTS United States
- FBIO United States
- Employees
- GUTS N/A
- FBIO N/A
- Industry
- GUTS
- FBIO Biotechnology: Pharmaceutical Preparations
- Sector
- GUTS
- FBIO Health Care
- Exchange
- GUTS NYSE
- FBIO Nasdaq
- Market Cap
- GUTS 58.8M
- FBIO 49.1M
- IPO Year
- GUTS 2024
- FBIO N/A
- Fundamental
- Price
- GUTS $1.68
- FBIO $1.88
- Analyst Decision
- GUTS Buy
- FBIO Strong Buy
- Analyst Count
- GUTS 1
- FBIO 2
- Target Price
- GUTS $10.00
- FBIO $21.00
- AVG Volume (30 Days)
- GUTS 938.9K
- FBIO 233.4K
- Earning Date
- GUTS 08-13-2025
- FBIO 08-12-2025
- Dividend Yield
- GUTS N/A
- FBIO N/A
- EPS Growth
- GUTS N/A
- FBIO N/A
- EPS
- GUTS N/A
- FBIO N/A
- Revenue
- GUTS $60,000.00
- FBIO $57,784,000.00
- Revenue This Year
- GUTS N/A
- FBIO $51.59
- Revenue Next Year
- GUTS N/A
- FBIO $44.74
- P/E Ratio
- GUTS N/A
- FBIO N/A
- Revenue Growth
- GUTS N/A
- FBIO N/A
- 52 Week Low
- GUTS $0.87
- FBIO $1.33
- 52 Week High
- GUTS $4.92
- FBIO $2.89
- Technical
- Relative Strength Index (RSI)
- GUTS 44.85
- FBIO 53.63
- Support Level
- GUTS $1.56
- FBIO $1.76
- Resistance Level
- GUTS $1.82
- FBIO $1.89
- Average True Range (ATR)
- GUTS 0.16
- FBIO 0.10
- MACD
- GUTS -0.05
- FBIO -0.01
- Stochastic Oscillator
- GUTS 16.92
- FBIO 75.00
About GUTS FRACTYL HEALTH INC
Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.
About FBIO Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.